Ensured LMIC access to molnupiravir

Dr. Reddys Laboratories, a multinational pharmaceutical company, is expanding access to generic molnupiravir in low- and middle-income countries.
  • Domain
  • Investment type
    Volume guarantee
  • Status
    Exit
  • Initial investment
    Public
  • Partnered in
    2022
  • Investment lead
    Chris Chen
  • Headquarters
    India
  • Program strategy
    COVID-19 Response

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.